Cefotil

Cefuroxime

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Pneumonia, Lyme Disease, Bronchitis, Bronchiectasis, Community Acquired Pneumonia, Gonorrhea, Infection, Infection,Urinary Tract, Infection,Soft Tissue

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefotil

Property	Description
Active ingredient	Cefuroxime
Form	Tablet, oral suspension, powder for injection
Pharmacological class	Second-generation cephalosporin antibiotic
Common purpose	To kill susceptible bacteria (bactericidal action)
Origin	Semisynthetic

What Type of Medicine is Cefotil (Cefuroxime)?

Cefotil is a prescription-only, semisynthetic antibiotic centered on the active ingredient Cefuroxime, and it belongs to the class of second-generation cephalosporins. Cefuroxime functions as an antibacterial agent that works by stopping the growth of bacteria. This classification defines it as a beta-lactam antibiotic with an expanded broad-spectrum of action, providing efficacy against a wider range of Gram-negative bacteria compared to earlier generations. Its semisynthetic nature contributes to its stability and absorption characteristics. Cefotil is a specific trade name for products containing Cefuroxime, often positioned for the treatment of susceptible infections in both adult and pediatric patient groups.

Composition and Forms: Understanding Cefotil's Ingredients

The therapeutic core of Cefotil is Cefuroxime, a single-ingredient product formulated in multiple ways to allow for different routes of administration. It is supplied either as Cefuroxime sodium for sterile powder for injection or as the oral form, Cefuroxime axetil, for use in tablets or suspension. Chemically, Cefuroxime axetil is a prodrug—an inactive precursor that is rapidly converted into the fully active Cefuroxime once absorbed from the gastrointestinal tract. This strategy ensures the active agent is efficiently delivered into the body when taken by mouth, which is beneficial for transitioning patients from injectable to oral therapy.

Cefotil's General Purpose as an Antimicrobial Agent

Cefotil's general purpose is to act as a bactericidal antimicrobial agent that directly eliminates susceptible bacteria by preventing them from properly building their essential cell walls. As a bactericidal agent, Cefuroxime binds to penicillin-binding proteins to inhibit cell-wall synthesis. This fundamental action of actively killing pathogens serves the critical general purpose of countering the presence and spread of harmful microbial agents throughout the body, such as in typical scenarios involving ear, nose, or throat infections.

Regulatory References

What side effects are possible with Cefotil?

Possible Side Effects and Safety Information

The safety profile of Cefotil (Cefuroxime), a second-generation cephalosporin, is structured by regulatory documents that classify potential adverse reactions based on frequency and affected body system.

System-Organ Classes and Documented Adverse Reactions

The most frequently reported reactions are classified as Common, affecting 1% to 10% of patients. These commonly reported effects primarily involve Gastrointestinal Disorders, such as diarrhea, nausea, and vomiting. Reactions affecting the Nervous System include headache and dizziness. Within Blood and Lymphatic System Disorders, a transient increase in eosinophils is commonly documented.

Transient increases in liver enzyme levels, such as AST and ALT, are common findings in the Hepatobiliary Disorders classification. Uncommon effects include a positive Coomb's test, which may interfere with blood cross-matching, and reductions in certain blood cell counts (leukopenia, thrombocytopenia).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight Serious Adverse Reactions, including potentially fatal Anaphylactic Reactions and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome. The use of Cefotil, like other antibiotics, is associated with the risk of Clostridioides difficile-Associated Diarrhea (CDAD), which can occur during or subsequent to administration.

Safety caution is warranted for certain patient groups. Individuals with Renal Impairment are at higher risk of elevated drug concentrations and potential neurotoxicity (e.g., seizures), necessitating careful monitoring. Furthermore, Cefotil is contraindicated in patients with a known history of hypersensitivity to any cephalosporin or other beta-lactam antibiotic class.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cefotil (Cefuroxime) overdose is defined by potential central nervous system (CNS) manifestations and specific criteria for seeking immediate medical attention. Overdosage of cephalosporins may induce cerebral irritation, which is documented to potentially progress to convulsions or seizures.

When Immediate Medical Help is Required

Urgent medical intervention is explicitly required if an overdose results in severe clinical signs. Call emergency services immediately if the individual experiences a seizure, collapses, develops trouble breathing, or cannot be awakened. Contacting the poison control helpline is also a mandated action in any suspected overdose scenario.

Official Management and Considerations

No specific antidote for Cefuroxime overdose is known. Management focuses on supportive care and the immediate discontinuation of the drug. Regulatory documents note that measures such as hemodialysis or peritoneal dialysis can be used to reduce high serum levels of Cefuroxime. A critical population-specific consideration is the elevated risk of toxicity and CNS effects in individuals with impaired renal function, as reduced drug clearance may lead to prolonged high serum concentrations.

Therapeutic Uses of Cefotil

What Cefotil Treats: Main Uses and Benefits

Cefotil (Cefuroxime) may be part of symptomatic management for susceptible bacterial infections across key body systems, which provides support that helps ease the overall symptom burden. Cefuroxime is commonly used to treat infections of the skin, ears, sinuses, throat, and airways. The medication is relevant in contexts involving heightened systemic burden, and is commonly used to help with acute or unstable symptom patterns in conditions such as acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, otitis media, and various skin and urinary tract infections.

Relief in Acute Symptomatic Episodes

Cefotil is applied across domains where additional symptomatic support is needed. It may assist with managing symptom clusters that may become intense or disruptive, such as fever, ear pain, sinus pressure, localized swelling, and spreading inflammation. This action may help patients cope more steadily with symptom fluctuations.

“It contributes to easing the overall symptom load and may support patients in maintaining day-to-day comfort during symptomatic periods.”

In a preventative context, Cefotil is commonly used in settings where short-term symptomatic assistance is needed, such as when administered as surgical prophylaxis to help reduce the risk of pain and inflammation that may arise from a post-operative infection.

Quick Fact: Symptom Management in Respiratory Conditions

Cefotil is often used during phases when symptoms become more noticeable, particularly for lower respiratory tract conditions where it assists with managing the symptoms related to physical discomfort and systemic imbalance.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Cefotil (Cefuroxime) eligibility rules are strictly defined by regulatory authorities based on patient population, allergy history, and pre-existing conditions.

Contraindicated Populations

Classification	Official Regulatory Statement
Contraindicated	Patients with known hypersensitivity to Cefuroxime, the cephalosporin class, or a history of severe allergy (e.g., anaphylaxis) to any other beta-lactam antibiotic (like penicillins) [SmPC/FDA].

Age and Physiological Limitations

Age Group / Status	Eligibility/Restriction (Official Labeling)
Infants (< 3 months)	Use not established: Safety and efficacy have not been established [FDA Label].
Pediatric (3 mos–12 yrs)	Approved for use with the oral suspension form for specific indications [FDA Label].
Pregnancy / Lactation	Conditional: Use is restricted and only recommended if the benefit outweighs the risk; Cefuroxime is present in human milk [FDA Label].

Condition-Based Restrictions

Use is restricted or requires caution in patients with: Markedly Impaired Renal Function ( CrCl < 30 mL/min), requiring a dose adjustment due to slower drug elimination; a history of Colitis or other severe Gastrointestinal Disease; or Phenylketonuria (PKU), if using the oral suspension which contains phenylalanine [SmPC/FDA].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several interactions concerning the use of Cefotil (cefuroxime axetil) with other medications and products. These interactions are primarily focused on maintaining drug effectiveness and managing systemic exposure.

Documented Pharmacological Interactions

Interacting Product Category	Official Regulatory Statement
Drugs that Reduce Gastric Acidity (e.g., antacids, H2 antagonists)	Coadministration may result in lower bioavailability (reduced absorption) of cefuroxime.
Probenecid (a uricosuric medicine)	Concomitant use increases systemic exposure (higher blood concentration) to cefuroxime and is officially not recommended.
Oral Contraceptives	Use may reduce the efficacy of oral contraceptives due to effects on gut flora.

Interaction Profile Summary

The official interaction profile is structured to guide against potential therapeutic failure (due to reduced absorption or contraceptive efficacy) and against increased toxicity (due to decreased clearance by probenecid). The coadministration restriction for Probenecid represents the most significant documented constraint on combined use.

Mechanism of Action

Molecular Targeting of Bacterial Cell Wall Construction

Cefotil's mechanism is driven by its active ingredient, Cefuroxime, a beta-lactam antibiotic that targets essential bacterial enzymes called Penicillin-Binding Proteins (PBPs). Cefuroxime acts as an irreversible inhibitor, covalently binding to and inactivating the PBPs—specifically PBP 3 and PBP 1a/1b—which are critical for the final cross-linking stage of peptidoglycan synthesis. This interference is the primary molecular event that leads to compromised integrity of the bacterial structure.

Mechanistic Cascade to Bactericidal Action

The inhibition of the PBPs results in a structurally defective cell wall that can no longer withstand the internal osmotic pressure of the bacterium. This structural compromise triggers the activation of the microbe's own autolytic enzymes (autolysins), which actively degrade the already weakened cell wall. This combined effect causes the bacterial cell to rapidly lyse and rupture, producing the bactericidal activity (pathogen cell death), which is the intended physiological consequence of the mechanism.

Stability Against Bacterial Defensive Enzymes

As a second-generation cephalosporin, Cefuroxime possesses enhanced stability that allows it to resist hydrolysis by certain beta-lactamase enzymes produced by resistant bacteria. This stability permits the Cefuroxime molecule to remain functionally intact, allowing it to inhibit the PBPs even in the presence of certain beta-lactamase enzymes, which preserves the mechanistic potential of the molecule.

Dosage and Administration Information

Administration Guidelines for Cefotil (Cefuroxime)

The usage of Cefotil is governed by specific instructions outlined in labeling, which detail the correct methods for administration, dosing, and duration of the prescribed course. The medicine is supplied in forms suitable for oral use (tablets and suspension) and parenteral use (intravenous or intramuscular injection).

Dosing and Administration Patterns

The standard dosing regimen is highly dependent on the type of form and route selected. Oral Cefotil is typically prescribed for administration every 12 hours (twice daily). The standard oral dose for many adult indications is 250 mg or 500 mg per dose. In contrast, the injectable form is commonly dosed every 8 hours, with doses ranging from 750 mg to 1.5 g per administration, potentially increasing in frequency for severe conditions.

Contextual Use Instructions

Specific conditions govern the intake of the oral forms: the tablets must be swallowed whole and may be taken with or without food. However, the oral suspension must be taken with food to ensure optimal absorption. The tablet and suspension forms are not bioequivalent and should not be interchanged on a milligram-per-milligram basis.

Adjustments and Course Duration

Labeling indicates dose modification for patients with reduced renal function. The dosing interval is lengthened according to the patient’s creatinine clearance to prevent accumulation. The total length of therapy is generally a fixed, short-term course, most commonly lasting 7 to 10 days.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Cefotil (Cefuroxime)

Evidence for Acute Respiratory and Ear Infections

Research was studied for conditions involving the respiratory tract and middle ear, which are often conditions characterized by fluctuating or episodic manifestations. These studies, primarily Randomized Controlled Trials (RCTs) and Systematic Reviews, were evaluated in both pediatric patients (starting from 3 months of age) and adults.

In research for acute otitis media, studies used in research exploring how symptoms change over time and monitored outcomes related to physical discomfort, such as clinical response and bacteriological response. These trials monitored responses over defined time intervals, typically tracking patients for up to one month post-treatment. For acute bacterial exacerbations of chronic bronchitis, research examined short-term symptom changes, focusing on outcomes related to systemic imbalance, such as clinical response and changes in specific respiratory symptoms. Studies also monitored bacterial eradication rates, often describing patterns observed against specific pathogen strains.

Evidence for Skin, Urinary, and Other Infections

Cefotil research examined uncomplicated skin and skin-structure infections (SSTI) and uncomplicated urinary tract infections (UTI) primarily through Randomized Controlled Trials. These short-term trials monitored outcomes related to inflammatory or irritative states, such as the resolution of localized swelling and overall resolution status. Findings describe group patterns related to clinical response and bacterial eradication, and results apply only to the populations studied with uncomplicated infections. Data for certain groups remain insufficient for complex, deep, or severe infections.

Cefotil research examined patients with early Lyme disease (Erythema Migrans). RCTs and authoritative clinical guideline summaries describe research that monitored clinical response and the tracking the status of late-stage disease manifestations over an extended, long-term follow-up period. In the context of surgical prophylaxis, Meta-analyses of RCTs research examined outcomes related to systemic or functional imbalance by research examined outcomes related to reducing the incidence of surgical site infections (SSIs).

Areas of Uncertainty and Study Gaps

While Cefotil has been studied for its approved uses, the available evidence does have recognized limitations. Follow-up durations were limited in many trials, meaning the long-term effects are not fully established. Furthermore, evidence quality varies across studies, and comparative evidence is lacking in some areas. Data for certain groups remain insufficient, particularly for patients with very severe disease or those with complex, multiple co-existing chronic conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cefotil (FAQ)

Q: Is Cefotil a type of penicillin?

A: Cefotil is officially classified as a cephalosporin antibiotic, not a penicillin. Both are part of the larger beta-lactam class of antibiotics, but they are chemically distinct. According to regulatory information, Cefotil should not be used by patients with a known history of hypersensitivity (allergy) to any cephalosporin or other beta-lactam drugs, which includes penicillin.

Q: What is the difference between Cefotil and amoxicillin?

A: Cefotil (cefuroxime) is officially classified as a second-generation cephalosporin antibiotic. Amoxicillin, by contrast, belongs to the penicillin-class of antibiotics. This classification means they have different chemical structures and may be active against different types of bacteria, as described in official sources.

Q: How quickly does Cefotil typically start to work?

A: Official regulatory documents do not specify a fixed time for when clinical improvement might be observed. Cefotil is described as a bactericidal medicine, meaning its core action is designed to actively kill susceptible bacteria once it reaches therapeutic levels in the body. The full duration of therapy is typically a short course prescribed by a healthcare professional.

Q: Can Cefotil be used for urinary tract infections (UTIs)?

A: Yes, Cefotil is officially indicated for the treatment of certain uncomplicated urinary tract infections (UTIs) caused by susceptible strains of bacteria. The use is dependent on the specific infection and the guidance of a prescriber.

Q: Are there any food restrictions when taking Cefotil?

A: Official instructions differentiate between the forms of Cefotil. The tablets can be taken with or without food. However, the oral suspension (liquid) must be taken with food to ensure optimal absorption, as stated in the product information.

Q: Is it normal to feel tired while taking Cefotil?

A: Tiredness or fatigue is not listed as a common or uncommon side effect in official safety information. However, common adverse reactions listed in regulatory documents include dizziness and headache. These effects may contribute to a feeling of not being entirely well.

Q: How long is a typical course of treatment with Cefotil?

A: The usual duration of therapy for most infections treated with Cefotil is described in official labeling as being 7 to 10 days. The precise length of treatment is determined by the prescriber based on the infection being treated.

Q: Can Cefotil affect my liver or kidney function?

A: Official documents note that transient increases in liver enzyme levels (such as AST and ALT) have been reported. For the kidneys, dose adjustment is required for patients with reduced renal function to prevent drug accumulation.

Q: Can people with diabetes use Cefotil?

A: Official labeling contains a specific warning about potential laboratory test interference for people with diabetes. Cefotil can potentially cause a false-positive result for glucose (sugar) in the urine when certain non-enzymatic (copper reduction) tests are used.

Q: Is Cefotil safe for use during pregnancy, according to official sources?

A: Official information states that Cefotil should be prescribed only if the potential benefit justifies the potential risk, as described in official labeling. Studies in animals have not indicated evidence of fetal harm.

Q: What information is available about Cefotil use while breastfeeding?

A: Official documents report that the active ingredient in Cefotil is excreted in human milk in small quantities. Official labeling advises caution when Cefotil is administered to a nursing woman.

Q: How does Cefotil compare in chemical structure to first-generation cephalosporins?

A: The official classification of Cefotil as a second-generation cephalosporin is noted in regulatory documents. This indicates it has an expanded spectrum of activity and increased stability against certain beta-lactamase enzymes compared to first-generation agents.

Q: What is the role of Cefotil in treating respiratory tract infections?

A: Cefotil is officially indicated for treating several types of respiratory tract infections, including acute bacterial sinusitis, acute otitis media, and acute bacterial exacerbations of chronic bronchitis when caused by susceptible bacteria.

Q: What is the inactive ingredient composition in Cefotil tablets?

A: Regulatory documents list the active ingredient (Cefuroxime axetil) along with various excipients (inactive ingredients). For example, the oral suspension formulation is noted to contain phenylalanine, which is important information for certain patients, such as those with phenylketonuria (PKU).

Q: Has Cefotil been studied for treating chronic conditions?

A: The clinical trials summarized in official documents primarily focus on the use of Cefotil for treating acute infections over short, fixed courses. The available evidence does not focus on long-term treatment of chronic conditions.

Q: Is Cefotil known to cause yeast infections?

A: Official safety information includes a warning that treatment with Cefotil, like other antibiotics, may lead to microbial overgrowth. This can include an overgrowth of fungi, such as a Candida (yeast) infection.

Q: Is there a generic version of Cefotil available?

A: Cefotil is a trade name for the active ingredient Cefuroxime axetil. Official sources confirm that Cefuroxime axetil is the generic name for which multiple generic products are approved and available.

Q: Are there official warnings about driving or operating machinery while taking Cefotil?

A: Official documentation notes that Cefotil may cause side effects like dizziness. Therefore, official warnings state that patients should be aware of how the medicine affects them before driving or operating machinery.

Q: What are the official recommendations for disposal of unused Cefotil?

A: Official guidelines advise against throwing Cefotil into household trash or flushing it down a sink or toilet. The official guidance for disposal is often through a drug take-back program when one is available, or following local pharmaceutical waste regulations.

Q: How is Cefotil described in official documents regarding use in the elderly?

A: Official documents state that a dosage adjustment based solely on age is not necessary for elderly patients. However, if an elderly patient has reduced kidney function, the dose must be adjusted accordingly, as this is a known risk factor for drug accumulation.

Q: Can Cefotil affect the results of certain lab tests?

A: Yes, Cefotil is officially documented to interfere with certain lab tests. This includes the potential for a false-positive result in non-enzymatic urine glucose tests and a reported positive Coombs test.

Q: Are there studies examining Cefotil's resistance patterns?

A: Regulatory documents refer to the drug's activity against susceptible organisms and note its stability against certain bacterial defense mechanisms, such as beta-lactamase enzymes. Resistance patterns are often tracked in surveillance studies referenced by official bodies.

Q: What are the major allergic reaction symptoms officially linked to Cefotil?

A: Official safety warnings describe the risk of Serious Adverse Reactions, including potentially fatal Anaphylactic Reactions and severe skin reactions like Stevens-Johnson syndrome (SCARs).

Q: Is Cefotil commonly prescribed for ear infections?

A: Cefotil is officially indicated for the treatment of acute bacterial otitis media (middle ear infection) when it is caused by bacteria that are susceptible to the medicine. The use is determined by the specific diagnosis and the judgment of a healthcare professional.

Q: What are some common misunderstandings about Cefotil?

A: Official warnings focus on educating patients about the development of drug-resistant bacteria and the risk of overgrowth of other organisms, such as C. difficile bacteria. These are critical areas where clarification is provided in patient information.

Q: How should Cefotil be stored at home?

A: Official instructions specify that tablets should be kept at controlled room temperature and the reconstituted liquid suspension must be refrigerated (between 2 and 8 C). All forms must be securely stored out of the sight and reach of children.

Q: Is Cefotil a broad-spectrum antibiotic?

A: Official pharmacological descriptions classify Cefotil as a second-generation cephalosporin with an expanded spectrum of activity. This means the medicine is described as being active against a wide range of both Gram-positive and Gram-negative bacteria.

How should Cefotil be stored and disposed of?

How to Store and Dispose of Cefotil (Cefuroxime)

Official labeling defines strict storage and disposal requirements to ensure product quality and public safety.

Storage Conditions

Dosage Form	Temperature Requirement	Additional Handling
Tablets	Controlled room temperature	Protect from heat, moisture, and direct light; must be kept from freezing.
Reconstituted Suspension	Refrigerated (2 to 8 C)	Must be securely capped and kept from freezing. Discard after 10 days.

All forms of Cefotil must be kept out of the sight and reach of children.

Disposal Rules

Unused, expired, or discontinued Cefotil must be disposed of according to local pharmaceutical waste regulations. It is explicitly stated that the medicine must not be thrown into household trash or poured down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.